BioHarvest Sciences logo

BioHarvest Sciences(NASDAQ) BHST

Market Cap$25.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-83%
5 Year-85%
1 Year-85%
1 Month-19%
$1.49
+0.68%
+0.01Today
BioHarvest Sciences last closing stock price
MetricPriceDate
Last closeUSD 1.482026-10-06
BioHarvest Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.68%USD 1.472026-09-29
1 month-18.68%USD 1.822026-09-04
3 month-48.25%USD 2.862026-07-08
Year to date-71.48%USD 5.192025-12-31
1 year-84.97%USD 9.852025-10-06
3 year-69.97%USD 4.932023-10-06
5 year-84.89%USD 9.802021-10-07
Since inception-83.19%USD 8.802020-04-23

BioHarvest Sciences Financials at a Glance

Market Cap

$25.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$35.48M

Net Income (TTM)

-$11.07M

EPS (TTM)

-$0.52

P/E Ratio

-2.82

Dividend

$0.00

Beta (Volatility)

-28.40 (Low)

Price

$1.49

Volume

15,720.15

Open

$1.46

Previous Close

$1.49

Daily Range

$1.37 - $1.49

52-Week Range

$1.37 - $12.80

Estimated Earnings Date

Nov 12, 2026

BHST News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioHarvest Sciences

BioHarvest Sciences Inc. is a biotechnology company specializing in the development of innovative health and wellness nutraceutical solutions. The company utilizes a proprietary botanical synthesis platform technology to cultivate plant cells with enhanced concentrations of active ingredients, serving both direct consumers and third-party clients.

Products and Services
  • Health and wellness nutraceutical solutions
  • Contract Development and Manufacturing Operation (CDMO) services
  • Research and development in plant cell technology
Growth Outlook
  • Recent quarterly revenue reached $8.8 million, indicating strong market demand
  • TTM gross profit margin stands at approximately 59%, showcasing operational efficiency
  • Significant cash reserves of $16.2 million support ongoing research and expansion
Financial Highlights
  • Net income for Q2 2026 was -$3.7 million, reflecting ongoing investment in growth
  • Current ratio of 2.24 indicates strong liquidity position
  • Trailing twelve months (TTM) revenue of $34.2 million demonstrates consistent revenue generation
BioHarvest Sciences Inc. operates in the agricultural biotechnology sector, focusing on the extraction and synthesis of active ingredients from plant cells. The company has positioned itself to capitalize on the growing demand for health and wellness products, leveraging its unique technology to create high-quality nutraceuticals. The recent financial performance highlights a commitment to growth, with substantial investments in research and development aimed at expanding product offerings and market reach. The liquidity position remains robust, providing a solid foundation for future initiatives. As the health and wellness market continues to expand, BioHarvest Sciences Inc. is well-positioned to capture a significant share of this lucrative sector.
AI Generated • Sep 18, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

89

CEO

Zaki Rakib, PhD

Website

www.bioharvest.com

Headquarters

Vancouver, BC V6C 2T6, CA

BHST Financials

Key Financial Metrics (TTM)

Gross Margin

58.95%

Operating Margin

-17.99%

Net Income Margin

-31.21%

Return on Equity

-58.30%

Return on Capital

-14.10%

Return on Assets

-24.84%

Earnings Yield

-35.46%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$25.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.33M

Volume

15.72K

Avg. Volume

51.16K

Financials (TTM)

Gross Profit

$20.91M

Operating Income

-$6.38M

EBITDA

-$7.29M

Operating Cash Flow

-$8.71M

Capital Expenditure

-$2.24M

Free Cash Flow

-$10.95M

Cash & ST Invst.

$16.22M

Total Debt

$17.55M

BioHarvest Sciences Performance Analysis

BioHarvest Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,498,000161.6%
20232023-12-31USD 12,672,000130.5%
20242024-12-31USD 25,188,00098.8%
20252025-12-31USD 34,508,00037.0%
BioHarvest Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-306.5%
Q42025-12-31-0.0%
Q12026-03-31-6.2%
Q22026-06-303.9%
BioHarvest Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.869.0%
20232023-12-31USD -0.937.9%
20242024-12-31USD -0.80-14.1%
20252025-12-31USD -0.60-24.2%
BioHarvest Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3041.7%
Q42025-12-3114.3%
Q12026-03-31N/A
Q22026-06-30-33.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$8.84M

+3.8%

Gross Profit

$5.08M

-0.1%

Gross Margin

57.51%

N/A

Market Cap

$25.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$288.15K

N/A

Employees

89

N/A

Net Income

-$3.72M

+8.9%

EBITDA

-$2.02M

-43.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$16.22M

+335.3%

Total Debt

$17.55M

-16.8%

Accounts Receivable

$4.18M

+69.0%

Inventory

$5.78M

+40.0%

Long Term Debt

$13.13M

-12.0%

Short Term Debt

$4.42M

-28.4%

Return on Assets

-24.84%

N/A

Return on Invested Capital

-19.40%

N/A

Free Cash Flow

-$3.33M

-56.9%

Operating Cash Flow

-$2.77M

-83.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BIOXBioceres Crop Solutions Corp.
$0.33-1.70%
MERCMercer International Inc.
$0.25+4.08%
LVROLavoro Limited
$0.13+0.00%
AVDAmerican Vanguard Corporation
$1.71+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$113.12+0.55%
NUNu Holdings
$15.58-0.51%
NVDANvidia
$237.47-0.74%
BULLWebull
$5.89-19.09%

Questions About BHST

What is the current price of BioHarvest Sciences?

BioHarvest Sciences is trading at $1.49 per share.

What is the 52-week range for BioHarvest Sciences?

Over the past 52 weeks, BioHarvest Sciences has traded between $1.37 and $12.80.

How much debt does BioHarvest Sciences have?

As of the most recent reporting period, BioHarvest Sciences reported total debt of $17.55M.

How much cash does BioHarvest Sciences have on hand?

BioHarvest Sciences reported $16.22M in cash and cash equivalents in its most recent financial results.

What is BioHarvest Sciences’s dividend yield?

BioHarvest Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services